for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cellectis SA

ALCLS.PA

Latest Trade

8.99EUR

Change

-0.36(-3.85%)

Volume

33,156

Today's Range

8.96

 - 

9.46

52 Week Range

8.55

 - 

24.40

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
9.35
Open
9.33
Volume
33,156
3M AVG Volume
1.08
Today's High
9.46
Today's Low
8.96
52 Week High
24.40
52 Week Low
8.55
Shares Out (MIL)
42.45
Market Cap (MIL)
395.01
Forward P/E
-2.86
Dividend (Yield %)
--

Next Event

Cellectis SA at Cell & Gene Therapy Congress

Latest Developments

More

Cellectis Q2 Attributable Consolidated Net Loss Widens To $33 Mln

Cellectis Reports Q1 Adjusted Loss Per Share $0.26

Cellectis: FDA Clears UCARTCS1 IND Application

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cellectis SA

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Industry

Biotechnology & Drugs

Contact Info

8, rue de la Croix Jarry

+33.1.81691600

http://www.cellectis.com

Executive Leadership

Andre Choulika

Chairman of the Board, Chief Executive Officer, Member of the Executive Board

Eric Dutang

Chief Financial Officer, Member of the Executive Committee

Bill Montelth

Executive Vice President of Technical Operations, Member of the Executive Committee

David J.D. Sourdive

Executive Vice President, Strategic Initiatives, Member of the Executive Committee

Jon Voss

Executive Vice President, Member of the Executive Committee

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.1K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-1.720

2017

-2.466

2018

-1.636

2019(E)

-3.270
Price To Earnings (TTM)
--
Price To Sales (TTM)
38.62
Price To Book (MRQ)
1.21
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.14
LT Debt To Equity (MRQ)
12.56
Return on Investment (TTM)
-24.62
Return on Equity (TTM)
-20.45

Latest News

Latest News

BRIEF-Cellectis Reports New CAR Design To Control T-Cells

* REPORTED ON MONDAY NEW CAR DESIGN TO CONTROL CAR T-CELLS IN NON-LETHAL WAY

BRIEF-Cellectis Q4 Operating Loss Widens To 29.3 Million Dollars

* ANNOUNCED ON MONDAY, CELLECTIS REPORTS 4TH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS

BRIEF-Cellectis Reports End-Sept Cash Of 475.9 Million Dollars

* REPORTED ON TUESDAY TOTAL CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS $475.9 MILLION AS OF SEPTEMBER 30, 2018

BRIEF-Cellectis Operating Loss Widens To 21.7 Million US Dollars

* SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO

BRIEF-Cellectis Publishes Methods to Improve Clinical Use of Chimeric Antigen Receptor T-Cell Therapy

* ANNOUNCED ON TUESDAY NOVEL METHODS TO IMPROVE THE CLINICAL USE OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

BRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical Trial

* ANNOUNCED ON TUESDAY APPROVAL OF AMENDMENT TO PROTOCOL FOR PHASE 1 CLINICAL TRIAL OF UCART123 PRODUCT CANDIDATE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS

BRIEF-Cellectis Submits Investigational New Drug Application To FDA For UCART22

* SAID ON WEDNESDAY IT HAS SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE US FDA REQUESTING APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCART22

BRIEF-Cellectis Partners With Harvard’S Wyss Institute For Research On Human Genome

* SAID ON TUESDAY THAT HARVARD’S WYSS INSTITUTE PARTNERS WITH CELLECTIS TO RECODE HUMAN GENOME

BRIEF-Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares

* ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS)

BRIEF-Cellectis Q4 Operating Loss Widens To 27.8 Million Dollars

* REPORTED ON MONDAY Q4 TOTAL REVENUES OF $6.9 MILLION VS $13.0 MILLION YR AGO

France's Cellectis wins U.S patents for gene editing technology

The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

BRIEF-Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies

* SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

BRIEF-Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer

* CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Cellectis shares slump as death puts cell therapy tests on hold

French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis's recently approved Kymriah, has been forced to suspend testing following a patient death.

BRIEF-Cellectis says FDA places clinical hold of UCART123 studies following fatality

* ANNOUNCED TODAY HAVING RECEIVED NOTICE FROM FDA THAT CLINICAL HOLD WAS PLACED ON BOTH UCART123 ONGOING PHASE 1 STUDIES IN ACUTE MYELOID LEUKEMIA (AML) AND IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

BRIEF-Cellectis announces first patient dosed in clinical trial on UCART123

* ANNOUNCED ON THURSDAY, UCART123'S ADMINISTRATION TO FIRST PATIENT WITH BPDCN IN PHASE I CLINICAL TRIAL AT MD ANDERSON CANCER CENTER

BRIEF-Cellectis reports Q2 operating loss of 18.0 million euros

* SAID ON WEDNESDAY FIRST AML PATIENT TREATED WITH UCART123 ENROLLMENT ONGOING

BRIEF-Molmed signs development and production agreement with Cellectis

* SIGNS WITH CELLECTIS AGREEMENT FOR DEVELOPMENT AND PRODUCTION IN THE FIELD OF ALLOGENEIC CAR-T PRODUCTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cellectis is granted patent for CRISPR use in T-cells

* ANNOUNCED ON MONDAY ABOUT THE GRANT BY THE EUROPEAN PATENT OFFICE OF PATENT NO. EP3004337 FOR THE INVENTION OF USING RNA-GUIDED ENDONUCLEASES, SUCH AS CAS9 OR CPF1 FOR THE GENETIC ENGINEERING OF T-CELLS

BRIEF-Cellectis announces proposed Calyxt IPO of $100.0 million

* CELLECTIS: CALYXT ANNOUNCES PROPOSED INITIAL PUBLIC OFFERING OF $100.0 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up